ASSEMBLY BIOSCIENCES, INC. (ASMB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q4 '17: 9M Q1 '18: 11.9M Q2 '18: 12.8M Q3 '18: 14.4M Q4 '18: 14.8M Q1 '19: 15.1M Q2 '19: 15M Q3 '19: 14.9M Q4 '19: 16M Q1 '20: 16.2M Q2 '20: 52.5M Q3 '20: 82.8M Q4 '20: 79.1M Q4 '23: 7.2M Q1 '24: 12.9M Q2 '24: 21.5M Q3 '24: 28.3M Q4 '24: 28.5M Q1 '25: 32.2M Q2 '25: 33.2M Q3 '25: 37.2M Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q1 '24 Q4 '24 Q3 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -41.6M Q4 '16: -45.3M Q1 '17: -47.9M Q2 '17: -51M Q3 '17: -51.8M Q4 '17: -52.2M Q1 '18: -55M Q2 '18: -68.6M Q3 '18: -78.7M Q4 '18: -92.7M Q1 '19: -104.4M Q2 '19: -96.9M Q3 '19: -100.4M Q4 '19: -102.7M Q1 '20: -102.1M Q2 '20: -75.8M Q3 '20: -53.8M Q4 '20: -64.8M Q1 '21: -64.3M Q2 '21: -94.6M Q3 '21: -109.4M Q4 '21: -132.7M Q1 '22: -128.6M Q2 '22: -129.5M Q3 '22: -134M Q4 '22: -94.1M Q1 '23: -90.5M Q2 '23: -83.4M Q3 '23: -75.1M Q4 '23: -64.6M Q1 '24: -55.8M Q2 '24: -50.5M Q3 '24: -46.4M Q4 '24: -45.4M Q1 '25: -44.6M Q2 '25: -43.5M Q3 '25: -43.4M Q4 '25: -12.1M Q1 '26: -13.5M Q2 '26: -8.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -40.5M Q4 '16: -44.3M Q1 '17: -47.2M Q2 '17: -50.7M Q3 '17: -51.3M Q4 '17: -42.8M Q1 '18: -45.1M Q2 '18: -58.3M Q3 '18: -67.6M Q4 '18: -90.8M Q1 '19: -101.6M Q2 '19: -93.3M Q3 '19: -96.7M Q4 '19: -97.6M Q1 '20: -97.2M Q2 '20: -71.5M Q3 '20: -49.8M Q4 '20: -62.2M Q1 '21: -62.7M Q2 '21: -93.6M Q3 '21: -109M Q4 '21: -129.9M Q1 '22: -125.7M Q2 '22: -126.6M Q3 '22: -131M Q4 '22: -93.1M Q1 '23: -89M Q2 '23: -81.4M Q3 '23: -72.7M Q4 '23: -61.2M Q1 '24: -51.4M Q2 '24: -45.6M Q3 '24: -40.8M Q4 '24: -40.2M Q1 '25: -39.9M Q2 '25: -39M Q3 '25: -38.5M Q4 '25: -6.1M Q1 '26: -6.4M Q2 '26: -42K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '15: -16.8M Q4 '15: -18.7M Q1 '16: -24.2M Q2 '16: -26.6M Q3 '16: -29.3M Q4 '16: -34.9M Q1 '17: 9.3M Q2 '17: 3.7M Q3 '17: 590.6K Q4 '17: 1.9M Q1 '18: -48.6M Q2 '18: -52.3M Q3 '18: -58M Q4 '18: -65M Q1 '19: -73.4M Q2 '19: -78.4M Q3 '19: -80.3M Q4 '19: -84.1M Q1 '20: -85.3M Q2 '20: -87.5M Q3 '20: -58.2M Q4 '20: -63M Q1 '21: -71.1M Q2 '21: -69.8M Q3 '21: -99.3M Q4 '21: -93.4M Q1 '22: -87.6M Q2 '22: -83.6M Q3 '22: -84.6M Q4 '22: -84.5M Q1 '23: -80.4M Q2 '23: -76.1M Q3 '23: -70.2M Q4 '24: -51.1M Q1 '25: -56.2M Q2 '25: -55.8M Q3 '25: -55.7M Q4 '25: -41.1M Q1 '26: -39.8M Q2 '26: -38.5M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q3 '15: -17M Q4 '15: -18.8M Q1 '16: -24.3M Q2 '16: -26.6M Q3 '16: -29.3M Q4 '16: -35M Q1 '17: 9.1M Q2 '17: 3.5M Q3 '17: -24.5K Q4 '17: 995K Q1 '18: -49.5M Q2 '18: -53.2M Q3 '18: -58.5M Q4 '18: -65.3M Q1 '19: -75.2M Q2 '19: -80.1M Q3 '19: -82M Q4 '19: -85.6M Q1 '20: -85.5M Q2 '20: -87.9M Q3 '20: -58.7M Q4 '20: -63.4M Q1 '21: -74.6M Q2 '21: -72.9M Q3 '21: -102.4M Q4 '21: -96.5M Q1 '22: -87.6M Q2 '22: -83.6M Q3 '22: -84.7M Q4 '22: -84.6M Q1 '23: -80.5M Q2 '23: -76.3M Q3 '23: -70.3M Q4 '24: -51.1M Q1 '25: -56.2M Q2 '25: -55.8M Q3 '25: -55.8M Q4 '25: -41.2M Q1 '26: -39.8M Q2 '26: -38.6M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15B 30B 45B Q1 '18: 20.2M Q2 '18: 20.5M Q3 '18: 24.9M Q1 '19: 25.7B Q2 '19: 25.7M Q3 '19: 25.9M Q1 '20: 35.1B Q2 '20: 37.3M Q2 '21: 42.9M Q3 '21: 45.6M Q1 '22: 48.1M Q2 '22: 48.3M Q3 '22: 48.4M Q1 '23: 4.3M Q2 '23: 4.4M Q3 '23: 4.4M Q1 '24: 5.5M Q2 '24: 5.6M Q3 '24: 6.4M Q1 '25: 7.5M Q2 '25: 7.7M Q3 '25: 12.7M Q1 '26: 16.9M Q2 '26: 18.9M Q3 '18 Q3 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-180.00 -120.00 -60.00 0.00 60.00 120.00 180.00 Q3 '14: -4.24 Q4 '14: -3.15 Q1 '15: -2.87 Q2 '15: -2.76 Q3 '15: -1.81 Q4 '15: -1.88 Q1 '16: -1.88 Q2 '16: -2.06 Q3 '16: -2.35 Q4 '16: -2.57 Q1 '17: -2.74 Q2 '17: -2.93 Q3 '17: -2.97 Q4 '17: -162.30 Q1 '18: -162.29 Q2 '18: -162.81 Q3 '18: -162.97 Q4 '18: -4.00 Q1 '21: -1.70 Q2 '21: -2.44 Q3 '21: -2.76 Q4 '21: -3.02 Q1 '22: -2.81 Q2 '22: -2.77 Q3 '22: -2.84 Q4 '22: -23.09 Q1 '23: -27.07 Q2 '23: -30.44 Q3 '23: -33.25 Q4 '23: -13.40 Q1 '24: -10.60 Q2 '24: -8.70 Q3 '24: -6.92 Q4 '24: -6.72 Q1 '25: -6.23 Q2 '25: -5.58 Q3 '25: -4.79 Q4 '25: -0.55 Q1 '26: 0.08 Q2 '26: 1.21 Q3 '15 Q4 '16 Q1 '18 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.